Under Offer
Hilco is seeking offers to acquire the intellectual property of Immodulon Therapeutics Limited (In Administration) (the “Company”) on behalf of the Joint Administrators of the Company, Brian Milne and Craig Morrison of Quantuma Advisory Limited.
Immodulon Therapeutics Limited is a late-stage clinical biotechnology company founded in 2007 and based in the United Kingdom. The Company is researching a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies. The Company’s lead asset, IMM-101, a heat-killed Mycobacterium obuense, is being developed as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumours.
Unique elements of the Company’s research are protected through a suite of patents entitled, “IMM-101 as immuno-modulator, IMM-101 in pancreatic cancer plus GEM and IMM-101 combined with CPI” . These patents cover the focus of utilising IMM-101 in combination with various therapies.
The Company holds granted Orphan Drug Designations for heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer in the EU and US.
A significant element of proprietary know-how provides additional protection over the Company’s research.
The Company’s extensive organisational knowledge includes manufacturing know-how, clinical data, regulatory knowledge and combination therapy insights.
The Company holds data pertaining to clinical studies, IMM-101 has been studied intra-dermally in two oncology indications: advanced pancreatic cancer and advanced melanoma.
Immodulon Therapeutics Limited is highly regarded within the medical research industry. The Company’s advancements in immuno-oncology have been recognised through a number of awards and press coverage received, including the UK Bioindustry Association’s “Innovative Medicine” Award, as well as the “Excellence in Translational Research” honour from the European Association for Cancer Research. The Company’s proprietary IMM-101 therapy has been particularly recognised for its potential to transform cancer treatment.
The Company holds registered rights protecting the “Immodulon Therapeutics” brand name and logo.
The Company owns the copyright in the content of the professionally designed website hosted at immodulon.com.
Please register your interest and direct any questions in the first instance to Yasmin Saadi, +44 (0) 7766075798, ysaadi@hilcoglobaladvisors.co.uk or Alexander Muir +44 (0) 7593 562917, amuir@hilcoglobaladvisors.co.uk of Hilco, who will be able to provide access to further information on the signing of a confidentiality agreement and answer any questions you have at this stage. Bids are to be directed in writing to Hilco.
No warranties, express or implied, are provided in relation to any information or statements made in connection to this opportunity. The information contained herein, and within the project dataroom, has not been verified by Hilco and prospective purchasers must undertake their own due diligence to satisfy themselves as to the accuracy of all such information and any statements made. Hilco’s full Terms and Conditions apply. Hilco acts as agent for the Vendor who offers for sale only such right, title and interest the Company possesses in the assets.
Associate Director
Manchester Office
